CAMBRIDGE, MASSACHUSETTS — June 1, 2008. IntelligentMDx announced today They will presenting a collaborative poster with Drs. Manfred Brigl and Andrew Onderdonk from the Brigham and Women’s Hospital at the 108th General Meeting of the American Society of Microbiology being held in Boston, Mass. The poster is entitled “Innovative Bioinformatics Approach for Designing Primers and Probes for Better Diagnostics: Clinical Validation of Intelligent Medical Devices (IMD), Inc. Herpes Simplex Virus Reagents”.
IntelligentMDx develops and manufactures tests, under regulatory compliance, for a broad range of molecular based systems for use in clinical diagnostics, drug development and applied science applications. Our mission is to rapidly translate the needs of the clinician, patient and partners into very specific, highly sensitive, robust clinically impactful tests, thus enabling caregivers worldwide to provide care with certainty.
IntelligentMDx’s competitive advantage incorporates intelligent software with assay development and manufacturing expertise within a Quality System compliant with both ISO and FDA current regulations. Our uniquely integrated modular test development process provides clinically impactful and novel molecular testing solutions. The company is working to use its proprietary “symptom-based diagnostics” approach for disease detection. Our goal is to provide the end users with “smart” tests that detect several related diseases at once – more quickly and more economically than current standard individual tests. The quality and breadth of our product candidate pipeline, platform-agnostic approach, scientific team and strategic collaborations and partnerships is enabling us to become a fully integrated diagnostics company.
CONTACT: For more information on IntelligentMDx, visit www.IntelligentMDx.com or email info@intelligentMDx.com.